X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
STI-5656 (abivertinib maleate) is a pyrrolopyrimidine-based, mutant EGFR and BTK dual inhibitor with potential across multiple indications like Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL).
Lead Product(s): Abivertinib
Therapeutic Area: Oncology Product Name: STI-5656
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
In this pivotal study conducted in China, The overall response rate (ORR) for Fujovee (abivertinib), as confirmed by the IRC was 56.5% (118/209) and among them, 11 patients had complete responses with a CR rate of 5.3% (11/209) and median overall survival of 28.2 months.
Lead Product(s): Abivertinib
Therapeutic Area: Oncology Product Name: Fujovee
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
Fujovee (abivertinib) is a novel small molecule tyrosine kinase inhibitor that selectively targets both mutant forms of epidermal growth factor receptor as well as Bruton's tyrosine kinase and has been shown to inhibit extragonadal androgen production in preclinical models.
Lead Product(s): Abivertinib,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Fujovee
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
This is a value-inflection acquisition for Sorrento as it brings in multiple NCE drug product candidates, including the previously licensed Abivertinib as an anchoring small molecule drug product for treating many different cancers and autoimmune diseases.
Lead Product(s): Abivertinib
Therapeutic Area: Oncology Product Name: STI-5656
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 02, 2021
Details:
The acquisition will include late clinical stage drug Abivertinib, clinical stage candidate AC0058, preclinical stage candidate AC0939, and ACEA’s extensive proprietary library of small molecules, which potentially have applications for numerous human disease indications.
Lead Product(s): Abivertinib
Therapeutic Area: Oncology Product Name: STI-5656
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: $450.0 million Upfront Cash: Undisclosed
Deal Type: Merger April 05, 2021
Details:
The Brazil study is a Phase 2 Study of the Safety and Efficacy of STI-5656 in Subjects Hospitalized Due to COVID-19, particularly looking at the potential clinical benefits of the drug associated with its broad ability to reduce inflammatory cytokine storm.
Lead Product(s): Abivertinib
Therapeutic Area: Infections and Infectious Diseases Product Name: STI-5656
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
Abivertinib demonstrated in-vitro the ability to simultaneously lower multiple critical inflammatory cytokines associated with cytokine storm and poor prognosis in COVID-19 patients.
Lead Product(s): Abivertinib
Therapeutic Area: Infections and Infectious Diseases Product Name: STI-5656
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
Sorrento gets an exclusive license to ACEA’s Abivertinib, a novel small molecule tyrosine kinase inhibitor that selectively targets both mutant forms of the epidermal growth factor receptor and Bruton’s tyrosine kinase, across all indications for all territories outside China.
Lead Product(s): Abivertinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
